In focus · trending topic

Hematological Malignancies

2 stories · following the connections

Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a calcium release-activated calcium (CRAC) channel inhibitor and RP10107, a glutaminase inhibitor at the 2018 AACR Annual Meeting

By Nasdaq OMXApr 10, 2018, 11:00 AM UTC

Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class oral small molecule inhibitor of calcium release-activated calcium (CRAC) channel at 2017 AACR-NCI-EORTC International Conference, USA

By Nasdaq OMXOct 24, 2017, 11:00 AM UTC